Inhibikase Therapeutics, Inc.IKTNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+36.5%
5Y CAGR+102.7%
Year-over-Year Change
Research and development spending
3Y CAGR
+36.5%/yr
vs +34.8%/yr prior
5Y CAGR
+102.7%/yr
Recent deceleration
Acceleration
+1.7pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
34.2x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $30.60M | +77.8% |
| 2024 | $17.21M | +26.4% |
| 2023 | $13.62M | +13.2% |
| 2022 | $12.03M | +6.0% |
| 2021 | $11.36M | +1170.9% |
| 2020 | $893802.00 | -65.0% |
| 2019 | $2.55M | -30.0% |
| 2018 | $3.65M | +107.7% |
| 2017 | $1.76M | +107.4% |
| 2016 | $846386.00 | - |